ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
Unusual Whales
The company is anticipating a planned reduction of around 17% in its workforce, with estimated annual savings of about $10 million. This move is aimed at increasing the company's financial flexibility. Their main focus is on meeting upcoming regulatory and clinical goals, such as submitting the LOTIS-5 sBLA and releasing full LOTIS-7 data by the end of the specified time frame.
